SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis

Leukemia

Volumn 28, Issue 4, 2014, Pages 853-864

  Malfuson, J V ^a,b   Boutin, L ^b   Clay, D ^c,d   Thepenier C ^b   Desterke, C ^c,e   Torossian, F ^c,e   Guerton, B ^c,e   Anginot, A ^c,e   De Revel, T ^a,f   Lataillade, J J ^b,f   Le Bousse Kerdiles M C ^c,d,e  

^a PERCY MILITARY HOSPITAL   (France)

^b Centre de Transfusion Sanguine des Armees   (France)

^c INSERM   (France)

^d INSTITUT ANDRÉ LWOFF   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f Nuclear Medicine   (France)

Author keywords

acute myeloid leukemia; integrins; mesenchymal stromal cells; multidrug resistance; side population

Indexed keywords

ABC TRANSPORTER; CD34 ANTIGEN; HERMES ANTIGEN; INTEGRIN; VERY LATE ACTIVATION ANTIGEN 4;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CELL PROLIFERATION; CLONOGENESIS; DRUG TRANSPORT; ENGRAFTMENT; ENZYME ACTIVITY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; MESENCHYMAL STROMA CELL; MOUSE; NOD SCID GAMMA MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIDE POPULATION CELL;

ANIMALS; ANTIGENS, CD44; DRUG RESISTANCE, NEOPLASM; GTP-BINDING PROTEINS; HEMATOPOIETIC STEM CELLS; INTEGRIN ALPHA4BETA1; LEUKEMIA, MYELOID, ACUTE; MESENCHYMAL STROMAL CELLS; MICE; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84898472559     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.256     Document Type: Article

References (57)

1. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006; 6: 93-106. (Pubitemid 43361585)
2. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010; 466: 829-834.
3. Omatsu Y, Sugiyama T, Kohara H, Kondoh G, Fujii N, Kohno K et al. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity 2010; 33: 387-399.
4. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425: 836-841. (Pubitemid 37351467)
5. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004; 118: 149-161. (Pubitemid 38962572)
6. Yoshihara H, Arai F, Hosokawa K, Hagiwara T, Takubo K, Nakamura Y et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell 2007; 1: 685-697. (Pubitemid 350215333)
7. Umemoto T, Yamato M, Shiratsuchi Y, Terasawa M, Yang J, Nishida K et al. Expression of integrin beta3 is correlated to the properties of quiescent hemopoietic stem cells possessing the side population phenotype. J Immunol 2006; 177: 7733-7739. (Pubitemid 44846289)
8. Umemoto T, Yamato M, Ishihara J, Shiratsuchi Y, Utsumi M, Morita Y et al. Integrinalphavbeta3 regulates thrombopoietin-mediated maintenance of hematopoietic stem cells. Blood 2012; 119: 83-94.
9. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183: 1797-1806. (Pubitemid 26134320)
10. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-1034. (Pubitemid 32937383)
11. Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, Sorrentino BP. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA 2002; 99: 12339-12344.
12. Challen GA, Little MH. A side order of stem cells: the SP phenotype. Stem Cells 2006; 24: 3-12.
13. Hosokawa K, Arai F, Yoshihara H, Nakamura Y, Gomei Y, Iwasaki H et al. Function of oxidative stress in the regulation of hematopoietic stem cell-niche interaction. Biochem Biophys Res Commun 2007; 363: 578-583. (Pubitemid 47513670)
14. Uchida N, Fujisaki T, Eaves AC, Eaves CJ. Transplantable hematopoietic stem cells in human fetal liver have a CD34(\+) side population (SP)phenotype. J Clin Invest 2001; 108: 1071-1077. (Pubitemid 32946081)
15. Goodell MA, Rosenzweig M, Kim H, Marks DF, DeMaria M, Paradis G et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997; 3: 1337-1345. (Pubitemid 28011033)
16. Guo Y, Follo M, Geiger K, Lubbert M, Engelhardt M. Side-population cells from different precursor compartments. J Hematother Stem Cell Res 2003; 12: 71-82. (Pubitemid 36314701)
17. Preffer FI, Dombkowski D, Sykes M, Scadden D, Yang YG. Lineage-negative side-population (SP) cells with restricted hematopoietic capacity circulate in normal human adult blood: immunophenotypic and functional characterization. Stem Cells 2002; 20: 417-427.
18. Brunet de la Grange P, Vlaski M, Duchez P, Chevaleyre J, Lapostolle V, Boiron JM et al. Long-term repopulating hematopoietic stem cells and 'side population' in human steady state peripheral blood. Stem Cell Res 2013; 11: 625-633.
19. Storms RW, Goodell MA, Fisher A, Mulligan RC, Smith C. Hoechst dye efflux reveals a novel CD7(\+)CD34(-) lymphoid progenitor in human umbilical cord blood. Blood 2000; 96: 2125-2133.
20. Naylor CS, Jaworska E, Branson K, Embleton MJ, Chopra R. Side population/ABCG2-positive cells represent a heterogeneous group of haemopoietic cells: implications for the use of adult stem cells in transplantation and plasticity protocols. Bone Marrow Transplant 2005; 35: 353-360. (Pubitemid 40309480)
21. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001; 98: 1166-1173.
22. Moserle L, Ghisi M, Amadori A, Indraccolo S. Side population and cancer stem cells: therapeutic implications. Cancer Lett 2010; 288: 1-9.
23. Gross E, L'Faqihi-Olive FE, Ysebaert L, Brassac M, Struski S, Kheirallah S et al. B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells. Leukemia 2010; 24: 1885-1892.
24. Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Basecke J, Libra M et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 2009; 23: 25-42.
25. Becker PS. Dependence of acute myeloid leukemia on adhesion within the bone marrow microenvironment. Scientific World J 2012; 2012: 856467.
26. Matsunaga T, Fukai F, Miura S, Nakane Y, Owaki T, Kodama H et al. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia 2008; 22: 353-360. (Pubitemid 351250540)
27. Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002; 16: 1713-1724.
28. Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003; 9: 1158-1165. (Pubitemid 37173700)
29. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006; 12: 1167-1174. (Pubitemid 44527352)
30. Shiozawa Y, Havens AM, Pienta KJ, Taichman RS. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008; 22: 941-950. (Pubitemid 351689875)
31. Lataillade JJ, Clay D, Bourin P, Herodin F, Dupuy C, Jasmin C et al. Stromal cell-derived factor 1 regulates primitive hematopoiesis by suppressing apoptosis and by promoting G(0)/G(1) transition in CD34(\+) cells: evidence for an autocrine/paracrine mechanism. Blood 2002; 99: 1117-1129. (Pubitemid 34547062)
32. Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005; 205: 228-236. (Pubitemid 41428905)
33. Hurley RW, McCarthy JB, Verfaillie CM. Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation. J Clin Invest 1995; 96: 511-519.
34. Golebiewska A, Brons NH, Bjerkvig R, Niclou SP. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 2011; 8: 136-147.
35. Pierre-Louis O, Clay D, Brunet de la Grange P, Blazsek I, Desterke C, Guerton B et al. Dual SP/ALDH functionalities refine the human hematopoietic Lin-CD34\+ CD38-stem/progenitor cell compartment. Stem Cells 2009; 27: 2552-2562.
36. Mo W, Zhang JT. Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol 2012; 3: 1-27.
37. Stam RW, van den Heuvel-Eibrink MM, den Boer ML, Ebus ME, Janka-Schaub GE, Allen JD et al. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. Leukemia 2004; 18: 78-83. (Pubitemid 38159442)
38. Shapiro HM. Flow cytometric estimation of DNA and RNA content in intact cells stained with Hoechst 33342 and pyronin Y. Cytometry 1981; 2: 143-150. (Pubitemid 12217898)
39. Winkler IG, Pettit AR, Raggatt LJ, Jacobsen RN, Forristal CE, Barbier V et al. Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation. Leukemia 2012; 26: 1594-1601.
40. Wardyn GG, Rennard SI, Brusnahan SK, McGuire TR, Carlson ML, Smith LM et al. Effects of exercise on hematological parameters, circulating side population cells, and cytokines. Exp Hematol 2008; 36: 216-223.
41. Brusnahan SK, McGuire TR, Jackson JD, Lane JT, Garvin KL, O'Kane BJ et al. Human blood and marrow side population stem cell and Stro-1 positive bone marrow stromal cell numbers decline with age, with an increase in quality of surviving stem cells: correlation with cytokines. Mech Ageing Dev 2010; 131: 718-722.
42. Papayannopoulou T, Craddock C, Nakamoto B, Priestley GV, Wolf NS. The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci USA 1995; 92: 9647-9651.
43. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999; 283: 845-848.
44. Jetmore A, Plett PA, Tong X, Wolber FM, Breese R, Abonour R et al. Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34(\+) cells transplanted into conditioned NOD/SCID recipients. Blood 2002; 99: 1585-1593. (Pubitemid 34533030)
45. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307-1318. (Pubitemid 40629073)
46. Jing D, Fonseca AV, Alakel N, Fierro FA, Muller K, Bornhauser M et al. Hematopoietic stem cells in co-culture with mesenchymal stromal cells-modeling the niche compartments in vitro. Haematologica 2010; 95: 542-550.
47. Teixido J, Hemler ME, Greenberger JS, Anklesaria P. Role of beta 1 and beta 2 integrins in the adhesion of human CD34hi stem cells to bone marrow stroma. J Clin Invest 1992; 90: 358-367.
48. Verfaillie CM, Benis A, Iida J, McGlave PB, McCarthy JB. Adhesion of committed human hematopoietic progenitors to synthetic peptides from the C-terminal heparin-binding domain of fibronectin: cooperation between the integrin alpha 4 beta 1 and the CD44 adhesion receptor. Blood 1994; 84: 1802-1811.
49. Lundell BI, McCarthy JB, Kovach NL, Verfaillie CM. Activation of beta1 integrins on CML progenitors reveals cooperation between beta1 integrins and CD44 in the regulation of adhesion and proliferation. Leukemia 1997; 11: 822-829. (Pubitemid 27279732)
50. Thankamony SP, Sackstein R. Enforced hematopoietic cell E-and L-selectin ligand (HCELL) expression primes transendothelial migration of human mesenchymal stem cells. Proc Natl Acad Sci USA 2011; 108: 2258-2263.
51. Harburger DS, Calderwood DA. Integrin signalling at a glance. J Cell Sci 2009; 122(Part 2): 159-163.
52. Toole BP, Hyaluronan Slomiany MG. CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat 2008; 11: 110-121.
53. Deguchi T, Komada Y, Sugiyama K, Zhang XL, Azuma E, Yamamoto H et al. Expression of homing-associated cell adhesion molecule (H-CAM/CD44) on human CD34\+ hematopoietic progenitor cells. Exp Hematol 1999; 27: 542-552. (Pubitemid 29125064)
54. Challen GA, Boles NC, Chambers SM, Goodell MA. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell 2010; 6: 265-278.
55. Ghaffari S, Smadja-Joffe F, Oostendorp R, Levesque JP, Dougherty G, Eaves A et al. CD44 isoforms in normal and leukemic hematopoiesis. Exp Hematol 1999; 27: 978-993. (Pubitemid 29275386)
56. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, Sauerbrey A. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 2002; 16: 1443-1447.
57. Marie JP, Faussat-Suberville AM, Zhou D, Zittoun R. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia 1993; 7: 825-831. (Pubitemid 23210860)